

Supplementary Tables

Supplementary Table 1: Prognostic factors of overall survival in 73 patients with metastatic pancreatic neuroendocrine tumors requiring chemotherapy upfront (Group 3).

	Univariate analysis		Multivariate analysis	
	Median OS (95% CI)	<i>p</i> value	Hazard ratio (95% CI)	<i>p</i> value
Functioning tumors		0.42	-	-
Yes	Not reached			
No	64 (48-80)			
Number of metastatic sites		0.83	-	-
1	64 (25-105)			
≥2	64 (45-83)			
Liver tumor burden		0.54	-	-
<50 %	98 (66-130)			
≥50%	26 (0-83)			
Uptake on Octreoscan®		0.03	1.9 (0.6-6.8)	0.29
No	23 (-)			
Yes	98 (57-138)			
Uptake on TEP FDG			-	-
No	Not reached	0.75		
Yes	59 (35-93)			
Chromogranin A		0.29	-	-
≤2N, n (%)	98 (47-148)			
>2N, n (%)	51 (7-95)			
Grade		0.001	0.2 (0.1-0.7)	0.01
G1-2	98 (52-143)			
G3	27 (1-61)			
Tumor slope growth rate		<0.001		
Not available	115 (15-215)		Reference	
Progressive disease	98 (48-148)		0.26 (0.1-0.8)	0.014
Unknown	32 (23-40)		0.08 (0.01-0.4)	0.003

Abbreviations: OS, overall survival; CI, confidence interval; **TEP FDG, 18F-fluorodeoxyglucose positron emission tomography.**